Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database
Authors:
- Pier Paolo OlimpieriPOPier Paolo Olimpieri
- Fanny Erika PalumboFPFanny Erika Palumbo
- Gaetano GiuffridaGGGaetano Giuffrida
- Edoardo MilanettiEMEdoardo Milanetti
- Cecilia GozzoCGCecilia Gozzo
- Elisa Lucia ScebbaESElisa Lucia Scebba
- Giovanni Luca RomanoGiovanni Luca Romano
- Giovanni Enrico LombardoGLGiovanni Enrico Lombardo
- Andrea DuminucoAndrea Duminuco
- Calogero VetroCVCalogero Vetro
- Davide Giuseppe CastiglioneDCDavide Giuseppe Castiglione
- Giuseppe Alberto PalumboGiuseppe Alberto Palumbo
Open Access
- 18 October 2025
- journal article
- research article
- Published by MDPI AG in Hematology Reports
- Vol. 17 (5) , 54
Abstract
Background: Clinical trials comparing novel oral anticoagulants (NOACs) with warfarin reported a lower mortality rate and a reduced incidence of bleeding with NOACs. However, these studies do not allow for final conclusions about safety. Moreover, direct comparisons among NOACs are not available. Objectives: The aim of this study was to analyze data from EudraVigilance in order to compare OAC safety profiles. Methods: We searched for all suspected adverse drug reactions (ADRs) from OACs collected in the EudraVigilance up to March 2019. We calculated the reporting odds ratios (RORs) in order to assess the risk of reporting specific ADRs among drugs. Moreover, OAC safety profiles were investigated through correspondence analysis and visualized in contribution biplots. Results: A total of 244,149 individual case safety reports (ICSRs; 431,354 ADRs) related to OACs were retrieved from EudraVigilance. About 80% of ICSRs refer to NOACs, especially rivaroxaban. Gastrointestinal (Gastr) and central nervous system (Nerv) disorders were the most represented categories. More than 90% of ADRs were serious and almost 9% fatal, with the highest ROR reported for dabigatran. Both fatal and non-fatal ADRs reported for Vitamin K Antagonists (VKAs) differed from those reported for NOACs. Among the latter, dabigatran and rivaroxaban showed similar profiles, while apixaban differed from all other OACs, even in the case of fatal ADRs. Conclusions: As expected, data collected from EudraVigilance showed differences among drugs, probably related to their specific characteristics and/or the peculiar utilization in clinical practice. Further investigations are needed to better compare the safety profile of OACs.Keywords
This publication has 112 references indexed in Scilit:
- Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating AgentsAmerican Journal of Hematology, 2025
- Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasmsHemaSphere, 2024
- Retrospective analysis of gastrointestinal bleedings with direct oral anticoagulants reported to EudraVigilanceNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Pegylated Asparaginase‐Induced Liver Injury: A Case‐Based Review and Data From PharmacovigilanceThe Journal of Clinical Pharmacology, 2022
- Comparative study of adverse drug reactions among direct-acting oral anticoagulants and vitamin K antagonists using the EudraVigilance databaseNaunyn-Schmiedeberg's Archives of Pharmacology, 2021
- Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral AnticoagulantJAMA Internal Medicine, 2019
- Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillationCochrane Database of Systematic Reviews, 2018
- Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillationCochrane Database of Systematic Reviews, 2014
- New Oral Anticoagulants and the Risk of Intracranial HemorrhageJAMA Neurology, 2013
- Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long‐term follow‐upHematological Oncology, 2011